Utility of P2Y

Autor: Christian O, Bohan, Mirja M, Wirtz, Philipp, Hendrix, Oded, Goren, Clemens M, Schirmer, Civan, Islak, Dante M, Grassi, Shamsher, Dalal, Gregory, Weiner, Christoph J, Griessenauer
Rok vydání: 2020
Předmět:
Zdroj: World neurosurgery. 142
ISSN: 1878-8769
Popis: Dual antiplatelet therapy consisting of aspirin and clopidogrel is the standard of care for neurointerventional stenting and flow diversion. Platelet function testing has been increasingly performed to identify patients with a hypo- or hyper-response to clopidogrel. Ticagrelor has been a popular alternative antiplatelet agent for such patients. We assessed the role of platelet function testing in patients receiving ticagrelor and undergoing stenting or flow diversion.The data from patients who had undergone stent-assisted coiling or Pipeline flow diversion of a cerebral aneurysm with ticagrelor therapy at any point during their treatment course from May 2017 to August 2019 at a single academic institution in the United States were retrospectively reviewed. Platelet function testing was used to determine the P2YA total of 28 patients with 29 aneurysms were treated while receiving ticagrelor. Of the 29 aneurysms, 16 (55.2%) were treated with flow diversion and 13 (44.8%) with stent-assisted coiling. Four thromboembolic complications (13.8%) and no hemorrhagic complications developed. Of the 8 patients with ≥1 PRU value100, 4 (50%) had experienced a thromboembolic complication. The patients without a PRU value100 did not experience any complications.A risk of thromboembolic complications exists for patients receiving ticagrelor, which correlated with the PRUs in the present preliminary study. The findings from the present study suggest that the safe PRU range for patients receiving ticagrelor should be shifted to 0-100, which is lower than that of clopidogrel, thought to be 60-210. Further validation of the optimal PRU range for patients receiving ticagrelor is necessary.
Databáze: OpenAIRE
Externí odkaz: